ABL Texcell Diagnostics Announces Termination of Vela Diagnostics Letter of Intent

The proposed acquisition in Singapore and the United States will not proceed

WOIPPY, France--(BUSINESS WIRE)--Regulatory News:

ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6) (“Company”) an international life sciences company specializing in molecular diagnostics, healthcare software, clinical genomics and services supporting clinical research and biopharmaceutical development, announces the termination of the Letter of Intent relating to the proposed acquisition of Vela Diagnostics’ activities in Singapore and the United States, announced on September 21, 2026.

The Letter of Intent entered between Vela Diagnostics Holding Pte. Ltd., ABL Texcell Diagnostics and Advanced Biological Laboratories S.A. regarding the proposed acquisition of 100% of the share capital of Vela Operations Singapore Pte. Ltd. and Vela Diagnostics USA Inc. has been terminated.

Consequently, the transaction contemplated under the Letter of Intent will not proceed.

The Company continues to implement its development strategy across molecular diagnostics, clinical genomics, healthcare software, viral safety and specialized services supporting clinical research and biopharmaceutical development.

About ABL Texcell Diagnostics (ABLD)

ABL Texcell Diagnostics (ABLD) is an international company that specializes in innovative molecular biology tests and global solutions for its customers:

• Molecular polymerase chain reaction (PCR) detection – UltraGene, and
• Genotyping by DNA sequencing – DeepChek®.

ABL Texcell Diagnostics markets its entire product range globally through its own sales team and a network of exclusive distributors active on all continents. ABL Diagnostics' customers are academic clinical pathology laboratories, private reference laboratories and researchers willing to implement innovative and robust microbiological content in constant expansion.

Following the acquisition of TEXCELL’s operations, ABL Texcell Diagnostics is expanding its activities in the life sciences sector by integrating expertise and services dedicated to virology, biosafety testing and biopharmaceutical development support.

ABL Texcell Diagnostics has been marketing the products and services of its sister company CDL Pharma since the second half of 2025 through an intra-group strategy agreement.

An expanding portfolio of microbiology products:

• HIV – Drug resistance testing, including a whole genome kit.
• SARS-CoV-2, Tuberculosis, Hepatitis B and C – Advanced Detection Solutions.
• Microbiome and taxonomy – 16s/18s RNA-based analyses.
• Other viral and bacterial targets – Comprehensive molecular assays.

Integrated Solutions

• Real-time syndromic PCR tests
• Nadis® – Patient Medical Record used in more than 200 hospitals in France for the management of HIV and hepatitis.

ABL Texcell Diagnostics, headquartered in Woippy, is a public limited company listed on compartment B of the regulated market of Euronext in Paris (Euronext: ABLD – ISIN: FR001400AHX6). These molecular biology products generate recurring revenues and cover one of the largest portfolios of applications in microbiology.